These results suggest exosomal PD-L1 may be a potential therapeutic target, and a recent study reported that the inhibition of exosomal PD-L1 can enhance the anti-tumor immune response with immune checkpoint inhibitors in an animal model [34]. Here, CD274 is linked to neoplasm.